Alzheimer´s disease (AD) is the most prevalent neurodegenerative disorder in the elderly. The Bloomberg School of Public Health recently estimated that over 26 million people were living with AD in 2006 and that the number will grow to 106 million by 2050. Interventions that delay onset by just one year could reduce the 2050 figure by 12 million. This demonstrates the importance and social need of finding an effective therapeutic intervention. This complete two volume set gathers together some of the most promising examples of drugs now in pharmaceutical development, and new targets currently going through a validation process.
Discovery of Memoquin, a Multitarget-Directed Ligand (MTDL) for the Treatment of Alzheimer’s Disease / M. L. Bolognesi; A. Minarini; C. Melchiorre. - STAMPA. - (2010), pp. 213-226.
Discovery of Memoquin, a Multitarget-Directed Ligand (MTDL) for the Treatment of Alzheimer’s Disease
BOLOGNESI, MARIA LAURA;MINARINI, ANNA;MELCHIORRE, CARLO
2010
Abstract
Alzheimer´s disease (AD) is the most prevalent neurodegenerative disorder in the elderly. The Bloomberg School of Public Health recently estimated that over 26 million people were living with AD in 2006 and that the number will grow to 106 million by 2050. Interventions that delay onset by just one year could reduce the 2050 figure by 12 million. This demonstrates the importance and social need of finding an effective therapeutic intervention. This complete two volume set gathers together some of the most promising examples of drugs now in pharmaceutical development, and new targets currently going through a validation process.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
